Gemtuzumab Ozogamicin

Gemtuzumab Ozogamicin
Generic Name/API:Gemtuzumab Ozogamicin
Packaging:1 box contains single dose vial
Storage:Store at 2-8°C
Dosage:For dosage information, please check the General Information section.
Strength:4.5mg of lyophilized powder or cake in a single dose vial for reconstitution
Indication:Mylotarg is a targeted cancer therapy used to treat certain types of acute myeloid leukemia (AML), a fast-growing cancer of the blood and bone marrow. It is classified as an antibody-drug conjugate, meaning it combines a monoclonal antibody that specifically binds to CD33 - a protein commonly found on AML cells - with a powerful chemotherapy drug.

Mylotarg is indicated for the treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults, either in combination with standard chemotherapy or as a single agent for patients aged 75 or older, or those who have comorbidities that preclude intensive chemotherapy. It is also approved for the treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patients aged 1 month and older. 

Strength:

4.5mg of lyophilized powder or cake in a single dose vial for reconstitution

Dosage: 

Newly-diagnosed, de novo AML (combination regimen):  

  • Induction: 3 mg/m2 (up to one 4.5 mg vial) on Days 1, 4, and 7 in combination with daunorubicin and cytarabine. 
  • Consolidation: 3 mg/m2 on Day 1 (up to one 4.5 mg vial) in combination with daunorubicin and cytarabine.  

Newly-diagnosed AML (single-agent regimen):  

  • Induction: 6 mg/m2 on Day 1 and 3 mg/m2 on Day 8.  
  • Continuation: For patients without evidence of disease progression following induction, up to 8 continuation courses of Mylotarg 2 mg/m2 on Day 1 every 4 weeks.  

Relapsed or refractory AML(single-agent regimen):

  • 3 mg/m2 on Days 1, 4, and 7. 

Side effects

  • Fever, infection, bleeding, nausea, vomiting, constipation, rash, headache, liver problems, mouth sores, inflammation of the gut, and low white blood cell count (with or without fever).

Storage: 

  • 2-8°C
  • Do not freeze
  • Fatal hepatotoxicity may occur in the patients who are on mylotarg treatment. 
  • Infusion related reactions may occur which could be fatal sometimes. This could occur during or within 24hrs of mylotarg infusion. Therefore, premedication is required before infusing Mylotarg. 
  • Mylotarg is observed to be myelosuppressive, which may cause life threatening  hemorrhage due to prolonged thrombocytopenia.

Process to Import Medicine

FAQ

Mylotarg is a prescription medicine used to treat CD33-positive acute myeloid leukemia (AML)—a type of blood and bone marrow cancer. It is an antibody-drug conjugate (ADC) that combines a monoclonal antibody targeting CD33 on leukemia cells with a chemotherapy drug that destroys those cells.

Mylotarg is used to treat:

Newly diagnosed CD33-positive AML in adults (in combination with chemotherapy).

Newly diagnosed AML in adults not eligible for intensive chemotherapy (as monotherapy).

Relapsed or refractory CD33-positive AML in adults and children aged 1 month and older (as monotherapy).

Mylotarg is administered by intravenous (IV) infusion.

While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certification and possesses a valid operating license. These credentials confirm the supplier’s adherence to international standards for the proper distribution of medicinal products.

The cost of Mylotarg (Gemtuzumab Ozogamicin) in India varies as it is not locally approved and must be imported. Supplier availability, import charges, and international currency fluctuations affect the final price. For the latest cost details, contact 24/7QualityMeds at +91 9967979080.

To buy mylotarg (gemtuzumab ozogamicin) injection in India at a genuine price, contact 24/7QualityMeds. We assist with legal import compliance, sourcing from certified suppliers, and ensure safe delivery to your location.

Related products